Dopamine Agonists Market is expected to reach US$ 1,732.41 Million by 2033 | Emerging key players - Cerevel Therapeutics, Inhibikase Therapeutics, Inc., Neuraly Inc.

Market Size and Growth:

The Dopamine Agonists Market size reached US$ 1,148.88 Million in 2024 and is expected to reach US$ 1,732.41 Million by 2033, growing at a CAGR of 5.4 % during the forecast period 2025-2033.

The Dopamine Agonists Market report, published by DataM Intelligence, provides in-depth insights and analysis on key market trends, growth opportunities, and emerging challenges. Committed to delivering actionable intelligence, DataM Intelligence empowers businesses to make informed decisions and stay ahead of the competition. Through a combination of qualitative and quantitative research methods, it offers comprehensive reports that help clients navigate complex market landscapes, drive strategic growth, and seize new opportunities in an ever-evolving global market.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID): https://datamintelligence.com/download-sample/dopamine-agonists-market?sz

The Dopamine Agonists Market refers to the global industry focused on drugs that stimulate dopamine receptors to manage neurological and hormonal disorders. These therapies are widely used in treating Parkinson's disease, restless legs syndrome, and hyperprolactinemia, driven by rising neurological disease prevalence, aging populations, ongoing drug innovation, and expanding access to long-term neurological care.

Recent Key Developments of United States:

✅ December 2025: The Michael J. Fox Foundation highlighted tavapadon's FDA submission progress, noting its selective receptor targeting to potentially reduce side effects compared to broader dopamine agonists.

✅ November 2025: AbbVie advanced its tavapadon NDA following robust Phase 3 data across early and advanced Parkinson's patients, positioning it as a potential once-daily oral option.

✅ October 2025: AbbVie submitted a New Drug Application (NDA) to the FDA for tavapadon, a novel selective D1/D5 dopamine receptor partial agonist for Parkinson's disease treatment, based on positive Phase 3 TEMPO trial results showing motor symptom improvements.​​​

Recent Key Developments of Europe:

✅ December 2025: CHMP recommended approvals for various medicines, with sustained demand for non-ergot dopamine agonists in Parkinson's driven by aging populations and safety-focused innovations.

✅ November 2025: EMA emphasized safe use campaigns for receptor agonists in neurological contexts, indirectly supporting dopamine agonist adherence amid rising Parkinson's prevalence.

✅ October 2025: EMA CHMP meetings noted ongoing reviews but no specific new dopamine agonist approvals; market growth continued via generic adoption and cost pressures favoring affordable options.​

List of the Key Players in the Dopamine Agonists Market:

Teva Pharmaceuticals Inc.
GSK plc
UCB S.A.
Sun Pharmaceutical Industries Ltd.
Pfizer Inc.
Boehringer Ingelheim International GmbH
Wellona Pharma
Glenmark Pharmaceuticals Inc.
AdvaCare Pharma
Serum Institute of India Pvt. Ltd.

Emerging Players:

Cerevel Therapeutics
Inhibikase Therapeutics, Inc.
Neuraly Inc
Peptron

Speak to Our Analyst and Get Customization in the report as per your requirements: https://datamintelligence.com/customize/dopamine-agonists-market?sz

This Report Covers:

✔ Go-to-market Strategy.

✔ Neutral perspective on the market performance.

✔Development trends, competitive landscape analysis, supply side analysis, demand side analysis, year-on-year growth, competitive benchmarking, vendor identification, and other significant analysis, as well as development status.

✔Customized regional/country reports as per request and country level analysis.

✔ Potential & niche segments and regions exhibiting promising growth covered.

✔ Analysis of Market Size (historical and forecast), Total Addressable Market (TAM), Serviceable Available Market (SAM), Serviceable Obtainable Market (SOM), Market Growth, Technological Trends, Market Share, Market Dynamics, Competitive Landscape and Major Players (Innovators, Start-ups, Laggard, and Pioneer).

Segments Covered in the Dopamine Agonists Market:

By Product Type: Ergot-Based Dopamine Agonists, Non-Ergot-Based Dopamine Agonists.

By Route of Administration: Oral, Parenteral, Transdermal Patches.

By Application: Parkinson Disease, Antipsychotic Agents, Hyperprolactinemia, Type 2 Diabetes, Restless Legs Syndrome (RLS), Neuroleptic Malignant Syndrome, Others.

By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Regional Analysis:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Looking For Full Report? Get it Here: https://www.datamintelligence.com/buy-now-page?report=dopamine-agonists-market

Chapter Outline

⏩ Market Overview: It contains five chapters, as well as information about the research scope, major manufacturers covered, market segments, Dopamine Agonists market segments, study objectives, and years considered.

⏩ Market Landscape: The competition in the Global Dopamine Agonists Market is evaluated here in terms of value, turnover, revenues, and market share by organization, as well as market rate, competitive landscape, and recent developments, transaction, growth, sale, and market shares of top companies.

⏩ Companies Profiles: The Global Dopamine Agonists market's leading players are studied based on sales, main products, gross profit margin, revenue, price, and growth production.

⏩ Market Outlook by Region: The report goes through gross margin, sales, income, supply, market share, CAGR, and market size by region in this segment. North America, Europe, Asia Pacific, Middle East & Africa, and South America are among the regions and countries studied in depth in this study.

⏩ Market Segments: It contains the deep research study which interprets how different end-user/application/type segments contribute to the Dopamine Agonists Market.

⏩ Market Forecast: Production Side: In this part of the report, the authors have focused on production and production value forecast, key producers forecast, and production and production value forecast by type.

⏩ Research Findings: This section of the report showcases the findings and analysis of the report.

⏩ Conclusion: This portion of the report is the last section of the report where the conclusion of the research study is provided.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

People Also Ask:

◆ How big is the Dopamine Agonists Market in 2025?
◆ What is the projected growth rate of the Dopamine Agonists Market through 2033?
◆ Who are the key players in the Dopamine Agonists Market?
◆ Which region is expected to dominate the industry during the forecast period?

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.